Results - Announcements
Indoco Remedies Ltd share price declined by 3.30% to Rs 219.8 after the company's net profit tumbled by 70.25% to Rs 19.47 crore, while revenue from operations improved marginally 8.73% to Rs 506.92 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.54 lakh crore, gaining 3.34%. It has improved by 0.07% over last one week and edged lower by 3.01% in last one month while the market capitalization of Indoco Remedies Ltd has eased by 6.90% and 2.38% in the same period respectively.
Profit before tax (PBT) of Indoco Remedies Ltd stood at Rs 24.19 crore in Q3 FY26, crashing by 278.79% year-on-year, and nosediving by 68.88% quarter-on-quarter. EBITDA came in at Rs 44 crore, rising 5.13% YoY and improving 14.47% sequentially.
Total expenses increased by 10.23% to Rs 508.18 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 127.63 crore, soaring by 22.04% YoY, while employee benefits expense was at Rs 105.11 crore, easing 3.65% YoY.
For the TTM ended FY26, revenue from operations grew marginally by 9.24% to Rs 1792.94 crore, while net profit surged by 26.62% to Rs 98.7 crore, compared to previous TTM. EBITDA jumped by 10542% to Rs 138.47 crore, and PBT soared 43.22% to Rs 106.51 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 192.23 crore in FY26, as against Rs 93.94 crore in FY25.
Indoco Remedies Ltd plunged by 20.62% in last one year, underperforming the benchmark BSE Sensex which has reduced by 13.18% during the same period.